M-7007 Masitinib, Free Base, >99%

Synonyms : [AB-1010]

Related Terms : [Kinavet] [Masivet]

  • Size
  • US $
  • £
  • ¥
  • 10 mg
  • 37
  • 34
  • 30
  • 4,900
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 72
  • 66
  • 59
  • 9,400
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 112
  • 103
  • 92
  • 14,700
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 169
  • 156
  • 140
  • 22,200
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 213
  • 196
  • 176
  • 27,900
  • Add to Cart Qty:
  • In stock
  • 300 mg
  • 267
  • 246
  • 221
  • 35,000
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 410
  • 378
  • 340
  • 53,800
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 498.64
  • C28H30N6OS
  • [790299-79-5]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 200 mg/mL; very poorly soluble in ethanol or water; maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • Masitinib mesylate (AB1010) is a protein tyrosine kinase inhibitor. In vitro it has greater activity and selectivity than imatinib mesylate against the wild-type c-Kit receptor and the mutated form in the juxtamembrane region. It also inhibits the PDGF and FGFR3 receptors. BUI, B.N., et al. "Preliminary efficacy and safety results of Masitinib administered, front line in patients with advanced GIST. A phase II study." J. of Clin. Oncology 25: 10025 (ASCO Annual Meeting Proceedings Part I 2007).
  • A placebo-controlled phase III clinical trial of masitinib was performed in the dogs with nonmetastatic recurrent or nonresectable grade II or III mast cell tumors (MCT). Masitinib significantly increased overall time to tumor progression (TTP) compared with placebo, regardless of whether the tumors expressed mutant or wild-type KIT. Masitinib was generally well tolerated, with the most common adverse events being mild or moderate diarrhea or vomiting. Hahn, K.A., et al. "Masitinib is safe and effective for the treatment of canine mast cell tumors." J. Vet. Intern. Med. 22: 1301-1309 (2008).
  • Masitinib treatment of patients with imatinib-resistant tumors was encouraging. The safety profile of masitinib at 12mg/kg/day b.i.d. was favorable and compatible with a long-term regimen for the treatment of solid cancers. Soria, J.C., et al. "Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers." Eur. J. Cancer Jun 19 (2009) [Epub ahead of print].
  • Masitinib showed an oral bioavailability of ~60% in cats. Bellamy, F., et al. "Pharmacokinetics of masitinib in cats." Vet. Res. Commun. Jun 16 (2009) [Epub ahead of print].
  • Masitinib is the active ingredient in the drug product sold under the trade name Kinavet® in the U.S, and under the trade name Masivet® in Europe. This drug is currently approved in at least one country for use by veterinerians for treatment of recurrent (post-surgery) or nonresectable Grade II or III cutaneous mast cell tumors in dogs that have not previously received radiotherapy and/or chemotherapy except corticosteroids. THE MASITINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT KINAVET® OR MASIVET®, AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some use